Table 3.

Detection of rectal ACF by study arm

Study armNonaspirin users
DFMO + aspirin (n = 32)Double placebo (n = 30)Total (n = 62)PDFMO + aspirin (n = 24)Double placebo (n = 19)Total (n = 43)P
Baseline ACF0.1801a0.1175a
 Mean (SD)10.0 (10.34)6.9 (3.15)8.5 (7.84)11.0 (11.74)6.6 (2.85)9.0 (9.15)
 Median6.05.06.06.05.05.0
 Range5.0–56.05.0–17.05.0–56.05.0–56.05.0–14.05.0–56.0
12 Month ACF0.3631a0.4501a
 Mean (SD)3.4 (2.91)4.6 (3.99)4.0 (3.49)3.4 (2.92)4.5 (3.81)3.9 (3.34)
 Median3.04.54.02.55.04.0
 Range0.0–10.00.0–14.00.0–14.00.0–9.00.0–11.00.0–11.0
ACF absolute change0.0355a0.0227a
 Mean (SD)−6.6 (10.04)−2.4 (3.42)−4.5 (7.82)−7.6 (11.15)−2.1 (2.88)−5.2 (8.90)
 Median−5.0−3.0−4.0−5.0−2.0−4.0
 Range−47.0–5.0−10.0–7.0−47.0–7.0−47.0–1.0−6.0–3.0−47.0–3.0
ACF global assessment0.0203b0.0549b
 Reduced23 (74.2%)13 (44.8%)36 (60.0%)17 (73.9%)8 (44.4%)25 (61.0%)
 Not reduced8 (25.8%)16 (55.2%)24 (40.0%)6 (26.1%)10 (55.6%)16 (39.0%)
 Missing112112
  • aWilcoxon rank-sum P value.

  • bχ2 P value.